|
Austria-MI-MI Azienda Directories
|
Azienda News:
- GLP-1 Market: The Pipeline Expands – AHEAD OF THE CURVE® | TD Securities
The TD Cowen Insight Global GLP-1 sales in 2030 could reach US$139 billion, up from our US$101 billion forecast a little over a year ago Bracketing the size of a therapeutic category that could address one-fifth of the world's adult population is no small task, but therein lies opportunity Our updated model projects US$139 billion in
- Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 . . . - MSN
However, TD Cowen projects diabetes and obesity to account for 59% and 41% of the GLP-1 sales in 2030, respectively, and LLY to take roughly 48% share of the market just ahead of NVO’s 45% share
- No surprise: Lilly, Novo Nordisk were top revenue gainers in Q3
Cowen projects the type 2 diabetes and obesity market to mushroom to $102 billion by 2030 It’s a huge increase from the $30 billion market Cowen envisioned last year for 2030
- When Will GLP-1 Prices Drop? - Omada Health
Generic drugs behave more traditionally (vs “sticky” prices) and competition typically results in prices dropping It appears that the only hope for prices going down is 1) Medicare negotiating a lower price directly with manufacturers in 2027 or 2) a successful patent challenge that results in generic manufacturing
- GLP-1 boom causing pharma FOMO - bioprocessintl. com
In November 2023, investment banking company TD Cowen provided insight into the GLP-1 market The analysts said “GLP-1 sales could reach $102 billion by 2030, of which obesity is projected to contribute $41 billion ” “Two leaders in this field are expected to take roughly 44% and 52% share, respectively, of the global GLP-1 market in 2030
- GLP-1 Market Trends Future Outlook: What to Expect Over the Next . . .
Popular GLP-1s are expected to be targeted for price negotiations within the next few years, which might encourage a general price decrease across the market If a price cap is introduced, it will also limit potential future price increases for the drugs, meaning we will likely see a much steadier price level throughout the rest of the decade 3
- The Past, Present, and Future of GLP-1 Agonists - Aquest Consulting
In the US, nearly 2% of all adults (~5 million) are estimated to be currently using a GLP-1 (glucagon-like peptide-1) medication, and this is expected to climb to 6% (~15 million adults) by 2030 (1) GLP-1 receptor agonists, which are pharmacologic molecules that mimic a subgroup of gut -derived peptide
- GLP-1s: More than just obesity drugs | J. P. Morgan Asset Management
Biotech experts have called glucagon-like peptide-1 drugs (GLP-1s) the story of the decade Obesity is a debilitating chronic disease affecting roughly one in three Americans 1 Analysts’ forecasts, on average, call for these drugs to generate as much as USD100 billion in revenue by 2030 2
- A Heavy Price: The Economic and Social Costs of GLP-1 Weight Loss Drugs
While high costs currently limit access for many, increased competition and the introduction of generic versions of GLP-1s are expected to drive prices down Since its launch, the price of Ozempic has decreased by 40%, and financial analysts project prices to decrease by over 10% annually by 2027 (Murphy, 2024)
- The Heavy Price of GLP-1 Drugs – I-MAK
GLP-1 products have driven outsized market value growth: Since the launch of their first GLP-1 products, Novo Nordisk and Eli Lilly have experienced a combined $697 billion increase in market capitalization or total company value, which is 10 times greater than the $71 billion in U S revenue generated by the products over the same period
|
|